Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

627 - Triweekly versus weekly cisplatin concurrent with radiotherapy in locally advanced nasopharyngeal carcinoma


09 Oct 2016


Poster display


Mei Lan


Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376


M. Lan1, S. Wu1, F. Han1, M. Deng1, C. Chen1, Y. Huang1, Z. Duan2, J. Liao1, L. Tian3, L. Zheng3, T. Lu1

Author affiliations

  • 1 Radiation Oncology, Cancer Centre Sun Yat-Sen University, 510060 - Guangzhou/CN
  • 2 Radiation Diagnosis And Interventional Center, General Hospital of Chengdu Military Region, 610213 - Chengdu/CN
  • 3 Imaging Diagnosis And Interventional Center, Cancer Centre Sun Yat-Sen University, 510060 - Guangzhou/CN


Abstract 627


Comparative studies on triweekly and weekly cisplatin in locally advanced nasopharyngeal carcinoma (NPC) were all based on small sample size, and no definitive conclusion has been reached. The aim of this study was to compare the outcomes of concurrent chemoradiotherapy (CCRT) using two different schedules of cisplatin in patients with locally advanced NPC.


From January 2007 to December 2011, 1582 patients with stage II-IVb NPC, treated with CCRT alone were reviewed. Eight hundred and two patients received triweekly cisplatin (80-100 mg/m2 every three weeks, two to three cycles) and 780 patients received weekly cisplatin (30-40 mg/m2 every week, over five cycles). Clinical characteristics and treatment factors were well balanced in two groups. Overall survival (OS), disease–free survival (DFS), locoregional recurrence–free survival (LRRFS), distant metastasis-free survival (DMFS) and acute toxicity profiles were calculated.


Median follow-up time was 64 months (range, 4–194 months). For the entire cohort, the distant metastasis risk was decreased by 30% in the triweekly group than weekly group (hazard ratio [HR] = 0.70; 95% confidence interval [CI]: 0.49-0.99). Subgroup analysis revealed that triweekly cisplatin could further improve patients' 5-year DMFS (92.6% vs. 85.8%, P 


Triweekly cisplatin treatment is more effective than weekly cisplatin regimen in reducing distant metastases in patients with locally advanced NPC, especially for those with N3 or stage IV diseases and who were treated with IMRT.

Clinical trial identification

Legal entity responsible for the study



This research was supported by Grants from the Natural Science Foundation of China (81402244).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings